Drug intelligence / Profile preview

ikarugamycin

Development stage: Unknown
Modality: Small Molecules

Overview

Ikarugamycin is an antibiotic produced by species of Streptomyces. It exhibits antibacterial, anti-protozoal, and anticancer activities. Ikarugamycin prevents the formation of the bacterial 70S ribosomal subunit, inhibiting protein translation. It also inhibits clathrin-mediated endocytosis and CCP-dependent phagocytosis, preventing the uptake of oxidized LDL in macrophages.

Other names: IKA

Targets

70S ribosome (Bacterial protein synthesis ribosome complex)

Beyond the preview

Go deeper on ikarugamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ikarugamycin.

Explore the full profile